debt_leverage_profile
Minimal traditional debt; early-stage biotech funded primarily by equity; net-debt position near zero with significant cash burn rate.
Inferred
Agent_Inference
interest_rate_sensitivity
Low direct interest rate sensitivity; no significant floating-rate debt, but higher rates increase cost of future equity/debt capital raises.
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Dependence on GMP biologics manufacturing (likely US/EU CDMOs) and raw material inputs from China for cell therapy reagents.
Inferred
Agent_Inference
international_expansion_readiness
Effectively no international revenue currently; sovereign currency devaluation exposure is negligible at this pre-commercial stage.
Inferred
Agent_Inference
geographic_footprint
Primarily US-based operations and trials; no meaningful international revenue footprint; USD-denominated cost and capital structure.
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
High dependency on single or few CDMOs for T-cell manufacturing; substitution is costly and time-consuming, representing non-substitutable input risk.
Inferred
Agent_Inference
business_model_type_primary
Cloud disruption risk is moderate; critical IP and data hosted on third-party infrastructure but core product is cell therapy, not SaaS.
Inferred
Agent_Inference
business_model_type_secondary
Pre-commercial biopharma; secondary digital/analytical tools could face 30-day migration disruption but would not halt clinical programs immediately.
Inferred
Agent_Inference
switching_cost_profile
API coupling risk low; primary operational risk lies in manufacturing platform and regulatory CMC documentation lock-in, not software APIs.
Inferred
Agent_Inference
howey_test_risk_index
Revenue model is drug development (regulatory milestone-driven); Howey Test not directly applicable; equity financing risk of securities law scrutiny is standard.
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Limited GDPR/CCPA exposure currently; clinical trial patient data subject to HIPAA and FDA regulations; GDPR risk rises if EU trials expand.
Inferred
Agent_Inference
antitrust_exposure_flag
Minimal antitrust exposure; pre-commercial niche cell therapy company with no dominant market position in any therapeutic area.
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Currently 0% recurring revenue; 100% pre-revenue/pre-commercial; future revenue expected from milestone payments and eventual drug sales (transactional).
Inferred
Agent_Inference
monetization_vector
Anticipated monetization via licensing deals, partnership milestones, and eventual product sales; no subscription or retainer revenue model.
Inferred
Agent_Inference
pricing_architecture
No current pricing architecture; future oncology/infectious disease cell therapy pricing will likely benchmark against CAR-T market ($300K–$500K per patient).
Inferred
Agent_Inference
pricing_power_rating
Potential high pricing power if products achieve clinical differentiation; off-the-shelf allogeneic model could command premium over autologous competitors.
Inferred
Agent_Inference
target_gross_margin_bracket
Target gross margins of 60–80% achievable at scale for allogeneic cell therapies if COGS are managed via manufacturing efficiencies.
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider leakage problem; proprietary T-cell platform is protected; clinical and IP moat limits competitive imitation in near term.
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth will initially be headcount-sublinear if manufacturing scales via CDMO partnerships; internal headcount growth tied to R&D pipeline expansion.
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of growth is capital-intensive per program but potentially sublinear at commercial scale if allogeneic manufacturing yields improve.
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; Tevogen Bio is not a franchise business model.
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC economics depend on hospital/payer adoption; achieving formulary inclusion and reimbursement is the primary acquisition barrier.
Inferred
Agent_Inference
network_effect_present
No meaningful network effects; cell therapy is not a platform business; clinical outcomes data accumulation provides modest evidence-based moat over time.
Inferred
Agent_Inference
asset_efficiency_ratio
AI displacement risk low in core manufacturing; AI may accelerate target identification and trial design but does not displace proprietary T-cell biology.
Inferred
Agent_Inference
recession_resistance_tier
Moderate recession resilience; oncology and critical infectious disease treatments maintain demand but reimbursement and hospital budgets face pressure in downturns.
Inferred
Agent_Inference
customer_segment_primary
Primary future customers are hospital systems, oncology treatment centers, and specialty infusion centers; high concentration risk in early commercial phase.
Inferred
Agent_Inference
customer_segment_secondary
Secondary customers include government/institutional payers (Medicare, Medicaid, VA) and private insurers driving reimbursement coverage decisions.
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital is being allocated forward toward clinical-stage R&D and manufacturing partnerships; no significant legacy infrastructure to reallocate from.
Inferred
Agent_Inference
sec_cik
0001860871
High
SEC-EDGAR
ticker
TVGN
High
SEC-EDGAR